Vanity metrics like total revenue can be misleading. A startup might acquire many low-priced, low-usage customers without solving a core problem. Deep, consistent user engagement statistics are a much stronger indicator of genuine, 'found' demand than top-line numbers alone.

MedVee's use of 800 fake doctor accounts and alleged spam generated huge sales. However, the resulting FDA warnings and lawsuits create immense regulatory risk, driving the company's long-term enterprise value near zero. This mirrors the playbook of illegal vape companies that prioritized rapid, unsustainable growth over compliance.

The viral story of MedV, a telehealth company, framed as a solo founder's AI-powered success, is misleading. The reality reveals heavy reliance on outsourcing, thin margins, and highly aggressive, potentially illegal, marketing tactics to achieve its massive revenue run-rate.

Companies in regulated industries like pharma and nicotine can achieve rapid revenue growth by exploiting marketing's gray areas. However, this strategy attracts regulatory penalties and lawsuits, often reducing the company's long-term enterprise value to near zero due to the associated risks.

Entrepreneurs often celebrate high revenue as a key success metric, but without diligent expense tracking, they can actually be losing money. This focus on a vanity metric obscures the true financial health of the business.

The New York Times' story on MedVee framed it as a "billion-dollar company" based on a $1.8B revenue projection. This overlooks thin margins, low durability in a competitive market, and significant regulatory/legal risks, which would drastically lower a traditional valuation based on market cap or enterprise value.

Dynamic Signal generated millions in ARR, but analysis revealed customers treated the product like a one-off media buy, not a recurring software subscription. The high revenue hid an unsustainable, services-based model with low lifetime value.

Beyond outright fraud, startups often misrepresent financial health in subtle ways. Common examples include classifying trial revenue as ARR or recognizing contracts that have "out for convenience" clauses. These gray-area distinctions can drastically inflate a company's perceived stability and mislead investors.

Public market investors view revenue multiples as a shortcut to estimate a company's future earnings. A 6x revenue multiple implies a 20x earnings multiple once the business reaches 30% margins. This mental model shows that profitability and cash flow, not just revenue growth, are the ultimate drivers of valuation.